Dyne Therapeutics' Biologics License Application For Zeleciment Rostudirsen Got FDA Acceptance For Review To Treat Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the U.S. Food and Drug
Dyne Therapeutics got the FDA's green light to review their new medicine for a serious muscle disease called Duchenne muscular dystrophy. This is a big checkpoint, so watch to see if the FDA approves it—that would mean the company's hard work is paying off.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.